Rational discovery of dual-indication multi-target PDE/Kinase inhibitor for precision anti-cancer therapy using structural systems pharmacology
Table 2
Comparison of the performance of 3D-REMAP with other methods when predicting that kinase off-targets of levosimendan, which are ranked at the top 2.5%.